What does this research mean for the field?

Current chikungunya vaccines lack adequate human efficacy and safety data, making their recommendations for travelers controversial. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This research investigates the efficacy and safety of chikungunya vaccines for travelers, highlighting gaps in data.

June 1, 2026

Chikungunya Vaccines for Travelers: Unanswered Pragmatic Questions Persist

Key Points

This research investigates the efficacy and safety of chikungunya vaccines for travelers, highlighting gaps in data.
Review existing literature on chikungunya vaccine efficacy and safety.
Analyze safety signals associated with live virus vaccines.
Evaluate reasons for the loss of US approval for CHIK-LA.
CHIK-LA vaccine lost US approval due to safety concerns.
Data on vaccine efficacy remains inadequate for both available vaccines.
Live virus vaccines pose inherent risks that need further investigation.

Abstract

Chikungunya vaccine recommendations remain controversial. CHIK-LA has lost its US approval. Adequate data on human vaccine efficacy for either vaccine is lacking. Live virus vaccines have inherent risks. Given early safety signals, for CHIK-LA a robust human safety dataset is lacking.

Bookmark

Chikungunya Vaccines for Travelers: Unanswered Pragmatic Questions Persist

Key Points

Abstract

Cite This Study